Cargando…

Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease (coronavirus disease 2019, COVID-19) that may develop into a systemic disease with immunosuppression and death in its severe form. Myeloid-derived suppressive cells (MDSCs) are inhibitory cells that contribu...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez-Cortegana, Carlos, Sánchez-Jiménez, Flora, Pérez-Pérez, Antonio, Álvarez, Nerissa, Sousa, Alberto, Cantón-Bulnes, Luisa, Vilariño-García, Teresa, Fuentes, Sandra, Martín, Salomón, Jiménez, Marta, León-Justel, Antonio, de la Cruz-Merino, Luis, Garnacho-Montero, José, Sánchez-Margalet, Víctor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835351/
https://www.ncbi.nlm.nih.gov/pubmed/35154077
http://dx.doi.org/10.3389/fimmu.2021.801410
_version_ 1784649411725361152
author Jiménez-Cortegana, Carlos
Sánchez-Jiménez, Flora
Pérez-Pérez, Antonio
Álvarez, Nerissa
Sousa, Alberto
Cantón-Bulnes, Luisa
Vilariño-García, Teresa
Fuentes, Sandra
Martín, Salomón
Jiménez, Marta
León-Justel, Antonio
de la Cruz-Merino, Luis
Garnacho-Montero, José
Sánchez-Margalet, Víctor
author_facet Jiménez-Cortegana, Carlos
Sánchez-Jiménez, Flora
Pérez-Pérez, Antonio
Álvarez, Nerissa
Sousa, Alberto
Cantón-Bulnes, Luisa
Vilariño-García, Teresa
Fuentes, Sandra
Martín, Salomón
Jiménez, Marta
León-Justel, Antonio
de la Cruz-Merino, Luis
Garnacho-Montero, José
Sánchez-Margalet, Víctor
author_sort Jiménez-Cortegana, Carlos
collection PubMed
description Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease (coronavirus disease 2019, COVID-19) that may develop into a systemic disease with immunosuppression and death in its severe form. Myeloid-derived suppressive cells (MDSCs) are inhibitory cells that contribute to immunosuppression in patients with cancer and infection. Increased levels of MDSCs have been found in COVID-19 patients, although their role in the pathogenesis of severe COVID-19 has not been clarified. For this reason, we raised the question whether MDSCs could be useful in the follow-up of patients with severe COVID-19 in the intensive care unit (ICU). Thus, we monitored the immunological cells, including MDSCs, in 80 patients admitted into the ICU. After 1, 2, and 3 weeks, we examined for a possible association with mortality (40 patients). Although the basal levels of circulating MDSCs did not discriminate between the two groups of patients, the last measurement before the endpoint (death or ICU discharge) showed that patients discharged alive from the ICU had lower levels of granulocytic MDSCs (G-MDSCs), higher levels of activated lymphocytes, and lower levels of exhausted lymphocytes compared with patients who had a bad evolution (death). In conclusion, a steady increase of G-MDSCs during the follow-up of patients with severe COVID-19 was found in those who eventually died.
format Online
Article
Text
id pubmed-8835351
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88353512022-02-12 Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19 Jiménez-Cortegana, Carlos Sánchez-Jiménez, Flora Pérez-Pérez, Antonio Álvarez, Nerissa Sousa, Alberto Cantón-Bulnes, Luisa Vilariño-García, Teresa Fuentes, Sandra Martín, Salomón Jiménez, Marta León-Justel, Antonio de la Cruz-Merino, Luis Garnacho-Montero, José Sánchez-Margalet, Víctor Front Immunol Immunology Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a disease (coronavirus disease 2019, COVID-19) that may develop into a systemic disease with immunosuppression and death in its severe form. Myeloid-derived suppressive cells (MDSCs) are inhibitory cells that contribute to immunosuppression in patients with cancer and infection. Increased levels of MDSCs have been found in COVID-19 patients, although their role in the pathogenesis of severe COVID-19 has not been clarified. For this reason, we raised the question whether MDSCs could be useful in the follow-up of patients with severe COVID-19 in the intensive care unit (ICU). Thus, we monitored the immunological cells, including MDSCs, in 80 patients admitted into the ICU. After 1, 2, and 3 weeks, we examined for a possible association with mortality (40 patients). Although the basal levels of circulating MDSCs did not discriminate between the two groups of patients, the last measurement before the endpoint (death or ICU discharge) showed that patients discharged alive from the ICU had lower levels of granulocytic MDSCs (G-MDSCs), higher levels of activated lymphocytes, and lower levels of exhausted lymphocytes compared with patients who had a bad evolution (death). In conclusion, a steady increase of G-MDSCs during the follow-up of patients with severe COVID-19 was found in those who eventually died. Frontiers Media S.A. 2022-01-28 /pmc/articles/PMC8835351/ /pubmed/35154077 http://dx.doi.org/10.3389/fimmu.2021.801410 Text en Copyright © 2022 Jiménez-Cortegana, Sánchez-Jiménez, Pérez-Pérez, Álvarez, Sousa, Cantón-Bulnes, Vilariño-García, Fuentes, Martín, Jiménez, León-Justel, de la Cruz-Merino, Garnacho-Montero and Sánchez-Margalet https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Jiménez-Cortegana, Carlos
Sánchez-Jiménez, Flora
Pérez-Pérez, Antonio
Álvarez, Nerissa
Sousa, Alberto
Cantón-Bulnes, Luisa
Vilariño-García, Teresa
Fuentes, Sandra
Martín, Salomón
Jiménez, Marta
León-Justel, Antonio
de la Cruz-Merino, Luis
Garnacho-Montero, José
Sánchez-Margalet, Víctor
Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19
title Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19
title_full Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19
title_fullStr Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19
title_full_unstemmed Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19
title_short Low Levels of Granulocytic Myeloid-Derived Suppressor Cells May Be a Good Marker of Survival in the Follow-Up of Patients With Severe COVID-19
title_sort low levels of granulocytic myeloid-derived suppressor cells may be a good marker of survival in the follow-up of patients with severe covid-19
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8835351/
https://www.ncbi.nlm.nih.gov/pubmed/35154077
http://dx.doi.org/10.3389/fimmu.2021.801410
work_keys_str_mv AT jimenezcorteganacarlos lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT sanchezjimenezflora lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT perezperezantonio lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT alvareznerissa lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT sousaalberto lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT cantonbulnesluisa lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT vilarinogarciateresa lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT fuentessandra lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT martinsalomon lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT jimenezmarta lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT leonjustelantonio lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT delacruzmerinoluis lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT garnachomonterojose lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19
AT sanchezmargaletvictor lowlevelsofgranulocyticmyeloidderivedsuppressorcellsmaybeagoodmarkerofsurvivalinthefollowupofpatientswithseverecovid19